What novel therapies for idiopathic pulmonary arterial hypertension (IPAH) are being investigated?

Updated: Jul 08, 2020
  • Author: Ronald J Oudiz, MD, FACP, FACC, FCCP; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
  • Print

Clinical trials are under way to determine the safety and efficacy of several new therapies for IPAH. These include oral and inhaled prostanoids, phosphodiesterase inhibitors, tyrosine kinase inhibitors, and other novel agents. [50] Efforts are currently focused on prostacyclin analogues, newer endothelin antagonists, and PDE-5 inhibitors.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!